Two non-steroidal antiandrogens, designated MDV3100 and RD162, may be useful treatment for castration-resistant prostate cancer, Dr. Sawyers' team identified MDV3100 and RD162, diarylthiohydantoin compounds that remain active against the malignancy even in the face of elevated androgen receptor expression.
Testing in murine models of human castration-resistant prostate cancer, the authors found that RD162 and MDV3100 promoted tumor regression.
"While preliminary, these clinical data appear promising and validate the persistent role of androgen receptor in driving castration-resistant disease," the authors conclude.
Original Article From Here
"While preliminary, these clinical data appear promising and validate the persistent role of androgen receptor in driving castration-resistant disease," the authors conclude.
Original Article From Here
Post a Comment